A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Erenumab (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Sponsors Amgen
- 09 May 2017 Status changed from active, no longer recruiting to completed.
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017.